Table 3. Univariate logistic analysis for the occurrence of new lesions 9-month and ≤ 2 years after PCI.

	New lesion (+) 9-month N (%) = 31 (6)			New lesion (+) ≤ 2 years N (%) = 90 (17)
	OR	95%CI	p value	OR	95%CI	p value
Age, years	0.98	0.95–1.02	0.39	0.97	0.95–0.99	0.020
Sex: male	1.11	0.48–2.40	0.79	1.09	0.66–1.86	0.73
Body mass index, kg/m2	0.99	0.90–1.09	0.94	1.04	0.98–1.10	0.20
Risk factors
Hypertension	1.18	0.48–3.52	0.73	0.96	0.55–1.77	0.90
Diabetes mellitus	1.14	0.55–2.47	0.73	1.73	1.08–2.84	0.027
Dyslipidemia	1.31	0.56–2.84	0.50	1.02	0.58–1.71	0.92
Current smoker	1.99	0.58–12.51	0.35	1.36	0.68–2.55	0.36
History of smoking	9.71	4.57–21.20	＜0.001	1.52	0.83–2.67	0.16
Medication
Oral anticoagulation	1.81	0.65–4.35	0.21	1.28	0.64–2.40	0.45
Calcium-channel blocker	1.93	0.93–4.11	0.08	1.22	0.77–1.92	0.40
ACEI	0.62	0.18–1.64	0.39	0.76	0.40–1.37	0.39
ARB	2.00	0.96–4.25	0.06	1.07	0.68–1.69	0.76
β-blocker	3.75	1.78–8.29	＜0.001	1.00	0.61–1.60	0.99
Ezetimibe	0.39	0.02–1.94	0.37	0.86	0.32–1.98	0.75
Nitrates	0.67	0.25–2.36	0.48	0.79	0.32–1.71	0.58
Proton pump inhibitor	0.74	0.35–1.54	0.43	0.80	0.50–1.26	0.35
Laboratory data
Hemoglobin, g/dL	0.98	0.81–1.18	0.81	1.08	0.96–1.22	0.192
hs-CRP, mg/L	0.98	0.92–1.01	0.37	0.99	0.98–1.01	0.51
TC, mg/dL	1.01	0.99–1.02	0.054	1.01	1.00–1.02	0.003
LDL-C (F) ≥ 70 mg/dL	2.36	1.01–6.44	0.064	1.84	1.11–3.15	0.021
LDL-C (M) ≥ 70 mg/dL	2.40	0.98–7.21	0.078	1.81	1.07–3.19	0.032
HDL-C ＜40 mg/dL	1.13	0.50–2.91	0.77	1.21	0.72–1.99	0.47
Non-HDL-C ≥ 100 mg/dL	2.30	1.05–5.58	0.047	1.99	1.24–3.29	0.006
TG ≥ 150 mg/dL	0.95	0.39–2.10	0.91	1.11	0.66–1.83	0.69
Uric acid, mg/dL	0.91	0.71–1.17	0.49	0.99	0.84–1.16	0.89
FPG, mg/dL	0.99	0.98–1.00	0.20	1.00	0.99–1.00	0.26
eGFR, mL/min/1.73 m2	1.01	0.99–1.02	0.21	1.01	0.99–1.02	0.102
LVEF, %	1.00	0.98–1.03	0.90	1.01	0.98–1.02	0.56

Abbreviations: CI, confidence interval; OR, odds ratio. Other abbreviations are as in Table 1.